Dean Y. Maeda

3.0k citations

35 papers · 1.8k indexed · 1 hit paper · h-index 16

Oncology top 5%
Immunology top 5%
Molecular Biology
Pulmonary and Respiratory Medicine top 10%
Cellular and Molecular Neuroscience top 10%

Co-authors: John A. Zebala Andrew Coop Claudia Palena Lucas A. Horn Jeffrey Schlom Clint Allen Yvette Robbins Paúl E. Clavijo
Topics: Cancer Immunotherapy and Biomarkers (9 papers)Chemokine receptors and signaling (7 papers)Immune cells in cancer (6 papers)
Cited by: Immunology Oncology Toxicology
Journals: Nature Journal of the American Chemical Society Nucleic Acids Research
Partner nations: United States Austria Netherlands

In The Last Decade

Dean Y. Maeda

34 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effective combinatorial immunotherapy for castration-resistant prostate cancer

2017 396 citations John A. Zebala, Dean Y. Maeda et al. profile →

Peers

Countries citing papers authored by Dean Y. Maeda

Since Specialization

Citations

This map shows the geographic impact of Dean Y. Maeda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dean Y. Maeda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dean Y. Maeda more than expected).

Fields of papers citing papers by Dean Y. Maeda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dean Y. Maeda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dean Y. Maeda. The network helps show where Dean Y. Maeda may publish in the future.

Co-authorship network of co-authors of Dean Y. Maeda

This figure shows the co-authorship network connecting the top 25 collaborators of Dean Y. Maeda. A scholar is included among the top collaborators of Dean Y. Maeda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dean Y. Maeda. Dean Y. Maeda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Combined treatment with CDK4/6, CDK2, and CXCR1/2 inhibitors effectively halts the growth of BRAF wild-type melanoma tumors 2025 ·Frontiers in Oncology ·Jinming Yang,Weifeng Luo,Patricia A. Ward,Sheau‐Chiann Chen,John A. Zebala,Dean Y. Maeda,Chi Yan,Ann Richmond	0
2	Safety and efficacy of first-in-class CXCR1/2 inhibitor SX-682 in combination with pembrolizumab (pem) in patients (pts) with metastatic melanoma (mMEL) with disease progression on anti–PD-1 therapy. 2024 ·Journal of Clinical Oncology ·Sapna P. Patel,Anastasios Dimou,Adrienne I. Victor,Meghan J. Mooradian,Elizabeth I. Buchbinder,Leonel F. Hernandez‐Aya,Peter A. Prieto,Justine V. Cohen,Keith T. Flaherty,Stuart J. Kahn,Aaron D. Schuler,Dean Y. Maeda,John A. Zebala	10
3	Inhibition of the chemokine receptors CXCR1 and CXCR2 synergizes with docetaxel for effective tumor control and remodeling of the immune microenvironment of HPV-negative head and neck cancer models 2024 ·Journal of Experimental & Clinical Cancer Research ·Lucas A. Horn,Hanne Lind,Kristen Fousek,Haiyan Qin,Nika Rajabian,(unknown),(unknown),(unknown),Michael P. Kelly,Clint Allen,(unknown),Roberto Weigert,Dean Y. Maeda,John A. Zebala,Claudia Palena	4
4	Regression and Eradication of Triple-Negative Breast Carcinoma in 4T1 Mouse Model by Combination Immunotherapies 2023 ·Cancers ·(unknown),(unknown),(unknown),John A. Zebala,Dean Y. Maeda,Udo Rudloff,Joost J. Oppenheim,De Yang	9
5	Phase 1 Results of the First-in-Class CXCR1/2 Inhibitor SX-682 in Patients with Hypomethylating Agent Failure Myelodysplastic Syndromes 2022 ·Blood ·David A. Sallman,Amy E. DeZern,Arlene A. Gayle,Stuart J. Kahn,Eric Padron,Jeffrey E. Lancet,Andrew Kuykendall,Kendra Sweet,Onyee Chan,Dean Y. Maeda,Aaron D. Schuler,John A. Zebala,Rami S. Komrokji	11
6	Desmetramadol Is Identified as a G-Protein Biased µ Opioid Receptor Agonist 2020 ·Frontiers in Pharmacology ·John A. Zebala,Aaron D. Schuler,Stuart J. Kahn,Dean Y. Maeda	12
7	Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models 2019 ·Clinical Cancer Research ·Sarah Greene,Yvette Robbins,Wojciech K. Mydlarz,(unknown),Nicole C. Schmitt,Jay Friedman,Lucas A. Horn,Claudia Palena,Jeffrey Schlom,Dean Y. Maeda,John A. Zebala,Paúl E. Clavijo,Clint Allen	217
8	Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC 2019 ·JCI Insight ·Julia Kargl,Xiaodong Zhu,Huajia Zhang,Grace Yang,Travis J. Friesen,(unknown),Dean Y. Maeda,John A. Zebala,Jill McKay-Fleisch,Gavin Meredith,Afshin Mashadi-Hossein,Christina S. Baik,Robert H. Pierce,Mary W. Redman,Jeffrey C. Thompson,Steven Μ. Albelda,Hamid Bolouri,A. McGarry Houghton	127
9	Desmetramadol Has the Safety and Analgesic Profile of Tramadol Without Its Metabolic Liabilities: Consecutive Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trials 2019 ·Journal of Pain ·John A. Zebala,(unknown),Lynn R. Webster,(unknown),Aaron D. Schuler,Dean Y. Maeda,Stuart J. Kahn	9
10	Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy 2019 ·JCI Insight ·Lillian Sun,Paúl E. Clavijo,Yvette Robbins,Priya Patel,Jay Friedman,Sarah Greene,Rita Das,Chris Silvin,Carter Van Waes,Lucas A. Horn,Jeffrey Schlom,Claudia Palena,Dean Y. Maeda,John A. Zebala,Clint Allen	188
11	Boronic acid-containing CXCR1/2 antagonists: Optimization of metabolic stability, in vivo evaluation, and a proposed receptor binding model 2015 ·Bioorganic & Medicinal Chemistry Letters ·Dean Y. Maeda,(unknown),Aaron D. Schuler,Mark T. Quinn,Liliya N. Kirpotina,W.N. Wicomb,Richard L. Auten,Rambabu Gundla,John A. Zebala	12
12	Boronic acid-containing aminopyridine- and aminopyrimidinecarboxamide CXCR1/2 antagonists: Optimization of aqueous solubility and oral bioavailability 2015 ·Bioorganic & Medicinal Chemistry Letters ·Aaron D. Schuler,(unknown),Dean Y. Maeda,Mark T. Quinn,Liliya N. Kirpotina,W.N. Wicomb,S. Nicholas Mason,Richard L. Auten,John A. Zebala	12
13	Intestinal Transport of Aminopterin Enantiomers in Dogs and Humans with Psoriasis Is Stereoselective: Evidence for a Mechanism Involving the Proton-Coupled Folate Transporter 2012 ·Journal of Pharmacology and Experimental Therapeutics ·Alan Menter,(unknown),Christina Cherian,Larry H. Matherly,Lei Wang,Aleem Gangjee,(unknown),Dean Y. Maeda,Aaron D. Schuler,Stuart J. Kahn,John A. Zebala	15
14	IL-8 signaling does not mediate intra-amniotic LPS-induced inflammation and maturation in preterm fetal lamb lung 2009 ·American Journal of Physiology-Lung Cellular and Molecular Physiology ·Suhas G. Kallapur,Timothy J. M. Moss,Richard L. Auten,Ilias Nitsos,J. Jane Pillow,Boris W. Kramer,Dean Y. Maeda,John P. Newnham,Machiko Ikegami,Alan H. Jobe	27
15	Nicotinamide Glycolates Antagonize CXCR2 Activity through an Intracellular Mechanism 2009 ·Journal of Pharmacology and Experimental Therapeutics ·Dean Y. Maeda,Mark T. Quinn,Igor A. Schepetkin,Liliya N. Kirpotina,John A. Zebala	9
16	Bivalent inhibitors of glutathione S-transferase: The effect of spacer length on isozyme selectivity 2006 ·Bioorganic & Medicinal Chemistry Letters ·Dean Y. Maeda,Sumit Mahajan,William M. Atkins,John A. Zebala	21
17	N-Arylalkylpiperidines as High-Affinity Sigma-1 and Sigma-2 Receptor Ligands: Phenylpropylamines as Potential Leads for Selective Sigma-2 Agents 2002 ·Bioorganic & Medicinal Chemistry Letters ·Dean Y. Maeda,(unknown),(unknown),(unknown),Wayne D. Bowen,Andrew Coop	31
18	Identification of a New Class of Molecules, the Arachidonyl Amino Acids, and Characterization of One Member That Inhibits Pain 2001 ·Journal of Biological Chemistry ·Susan M. Huang,Tiziana Bisogno,Timothy J. Petros,Sai Y. Chang,(unknown),Robert E. Zipkin,Sivakumar Ramachandran,Andrew Coop,Dean Y. Maeda,Luciano De Petrocellis,Sumner Burstein,Vincenzo Di Marzo,James M. Walker	261
19	A sigma-1 receptor selective analogue of BD1008. a potential substitute for (+)-opioids in sigma receptor binding assays 2000 ·Bioorganic & Medicinal Chemistry Letters ·Dean Y. Maeda,(unknown),Wayne D. Bowen,Andrew Coop	19
20	Synthesis and Evaluation ofN,N-Dialkyl Enkephalin-Based Affinity Labels for δ Opioid Receptors 2000 ·Journal of Medicinal Chemistry ·Dean Y. Maeda,Jane E. Ishmael,Thomas F. Murray,Jane V. Aldrich	12

About Dean Y. Maeda

Dean Y. Maeda is a scholar working on Oncology, Toxicology and Immunology, having authored 35 papers that have together received 1.8k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (9 papers), Chemokine receptors and signaling (7 papers) and Immune cells in cancer (6 papers). The work is most often cited by research in Immunology (781 citations), Oncology (846 citations) and Toxicology (81 citations). Dean Y. Maeda has collaborated with scholars based in United States, Austria and Netherlands. Frequent co-authors include John A. Zebala, Andrew Coop, Claudia Palena, Lucas A. Horn, Jeffrey Schlom, Clint Allen, Yvette Robbins, Paúl E. Clavijo, Sarah Greene and Jay Friedman. Their work appears in journals such as Nature, Journal of the American Chemical Society and Nucleic Acids Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact